Form 4: Aptose Biosciences CEO Reports Ownership Changes

William G. Rice, CEO of Aptose Biosciences, reported changes in his beneficial ownership of company securities, including the disposition of common shares and various derivative securities.

Summary

• William G. Rice, Chair, President & CEO of Aptose Biosciences Inc., has reported transactions affecting his beneficial ownership of company securities.
• On June 30, 2026, Rice disposed of 613,252 common shares at a price of $1.72 per share, which was converted from C$2.41 per share using an exchange rate of C$1.4 = US$1.00.
• This disposition was part of a business arrangement agreement where a subsidiary of Hammi Pharmaceuticals Co. Ltd. acquired all outstanding shares of Aptose Biosciences.
• Additionally, various derivative securities, including employee stock options and warrants with different exercise prices and expiration dates, were also disposed of on the same date.
• These derivative securities included options with exercise prices ranging from $0.25 to $6.91 and underlying common shares ranging from 50,000 to 2,000,000.
• The filing notes that total options and option exercise prices are subject to adjustment due to previous reverse stock splits.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it details significant transactions by the CEO, it is a required disclosure related to an acquisition and does not inherently signal positive or negative performance of the underlying business.

Positives

• The disposition of shares and options was part of a pre-approved business arrangement, indicating a structured and transparent process.
• The acquisition of Aptose Biosciences by Hammi Pharmaceuticals suggests potential strategic value and future growth opportunities under new ownership.

Negatives

• The disposition of a significant number of common shares and derivative securities by the CEO may indicate a reduction in his direct stake and potentially signal a shift in strategic direction or personal financial planning.
• The conversion of Canadian dollar prices to US dollars with a specific exchange rate introduces a currency fluctuation element to the reported values.

Risks

• The filing does not explicitly mention any new or ongoing risks.
• The acquisition by Hammi Pharmaceuticals could lead to integration challenges or changes in operational focus that might pose risks to existing projects or personnel.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. However, the acquisition by Hammi Pharmaceuticals implies a future outlook under new ownership, the specifics of which are not detailed in this Form 4.

Management Comments

• The disposition was made pursuant to a board, shareholder, and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd.
• The agreement involved a subsidiary of Hammi acquiring all outstanding shares of the Issuer at a price of C$2.41 per share.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The nature of this filing, detailing a significant disposition of shares and options by the CEO in conjunction with an acquisition, is typical during M&A events. It provides transparency on how key executives are managing their holdings during such transitions.

Legal Proceedings

• The disposition of securities was made pursuant to a court-approved business arrangement agreement.

Related Party Transactions

• The disposition of securities by William G. Rice was part of a business arrangement with Hammi Pharmaceuticals Co. Ltd., a related party in the context of the acquisition.

Stakeholder Impact

• Shareholders: The acquisition by Hammi Pharmaceuticals at C$2.41 per share provides an exit opportunity for existing shareholders.
• Employees: The acquisition may lead to changes in employment status, roles, or company culture under new ownership.
• Management: William G. Rice's disposition of shares indicates a transition in his direct beneficial ownership as part of the acquisition.

Next Steps

• The acquisition of Aptose Biosciences by Hammi Pharmaceuticals is expected to be completed as per the business arrangement agreement.
• Further disclosures may follow regarding the integration of Aptose Biosciences into Hammi Pharmaceuticals.

Key Dates

Keywords

Form 4, SEC Filing, Aptose Biosciences, William G. Rice, Beneficial Ownership, Stock Disposition, Derivative Securities, Stock Options, Warrants, Merger, Acquisition, Hammi Pharmaceuticals